REPL · NASDAQ · STOCK
Replimune Group (REPL) Stock Analysis
$13.41
52W $1.50 – $16.33
62/100
$1.13B
-4.3
0.94
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is REPL Bullish or Bearish?
Bullish.
Innellis AI committee rates Replimune Group, Inc. (REPL) Buy with a composite score of 62/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.33 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.67 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -159.3% -- cheap may mean cheap for a reason — Value
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 23%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -159.3% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 61.7 to 61.7.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
56.7
Neutral
MACD Histogram
0.041
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$6.86
Resistance
$16.30
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$13.18
Above
EMA 21
$13.27
Above
EMA 50
$12.93
Above
EMA 200
$10.19
Above
Fundamental Analysis
Valuation
67
Growth
67
Profitability
0
Financial Health
86
Cash Flow
15
Valuation
P/E Ratio
-4.3×
P/B Ratio
12.30×
PEG Ratio
-0.71
Dividend Yield
0.00%
52W High
$16.33
52W Low
$1.50
Quality & Growth
ROE
-18893.8%
ROA
-9445.0%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
1.06
AI Fundamental Assessment
P/E ratio of -4.3 (inexpensive relative to a 15-40x range); Price-to-book of 12.3x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -188.9%; Return on assets of -94.4%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 5.23 (healthy short-term liquidity); Debt-to-equity of 1.06; Free cash flow per share is negative (-2.90); Most recent quarter beat estimates by 1.7%; EPS growth accelerating (+1.3% -> +5.3% QoQ); Average YoY EPS growth of 24.2%; Analyst estimates rising over recent quarters
Get the Full REPL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →